DOI 10.1080/09273948.2026.2690412
Upadacitinib in Refractory Vogt-Koyanagi-Harada Disease: A Case Report.
Аннотация
PURPOSE: To evaluate the role of Upadacitinib, a selective Janus kinase-1 (JAK-1) inhibitor, in the management of refractory Vogt-Koyanagi-Harada (VKH) disease.
METHODS
A 25-year-old male was diagnosed with bilateral VKH disease based on clinical findings and supportive investigations. He experienced multiple recurrences despite treatment with conventional therapies, including systemic corticosteroids, cyclosporine, mycophenolate mofetil (MMF), and adalimumab. The patient also demonstrated intolerance to systemic steroids. He was subsequently classified as having refractory VKH in both eyes and was initiated on oral Upadacitinib.
RESULTS
Following the initiation of oral Upadacitinib, a novel selective JAK-1 inhibitor, there was complete resolution of subretinal fluid (SRF), with no further recurrences observed during follow-up, resulting in sustained disease stability.
CONCLUSION
This case underscores the potential utility of selective JAK-1 inhibition in the management of refractory VKH disease, particularly in patients who are unresponsive to or intolerant of conventional corticosteroid and immunosuppressive therapies.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.